Research Article
Association of IGF-1 Level with Low Bone Mass in Young Patients with Cushing’s Disease
Table 1
Clinical and biochemical preoperative characteristics of young Cushing’s disease patients according to status of bone mineral density at diagnosis.
| | Variables | Without low bone mass | With low bone mass | value |
| | N (%) | 78 (51.32%) | 74 (48.37%) | | | Male N (%) | 9 (11.54%) | 24 (32.43%) | 0.0016 | | Female N (%) | 69 (88.46%) | 50 (67.57%) | | History of fragility fractures N | 0 | 10 | — | | Disease status | | Newly diagnosed N | 59 | 58 | 0.6351 | | Recurrence N | 13 | 9 | 0.1562 | | No remission after treatment N | 7 | 7 | 0.7453 | | Osteocalcin (ng/ml) | 5.84 (3.60–8.79) | 6.71 (3.60–8.90) | 0.7267 | | Decreased osteocalcin N (%) | 23 (41.07%) | 18 (40%) | 0.9132 | | VD-OH25 (nmol/L) | 48.45 (37.79–55.85) | 44.40 (37.47–53.75) | 0.2979 | | Decreased VD-OH25 N (%) | 31 (59.62%) | 28 (70%) | 0.3032 | | PTH (pg/ml) | 35.50 (25.30–54.20) | 48.45 (33.70–65.80) | 0.1828 | | Increased PTH N (%) | 8 (14.04%) | 7 (14%) | 0.9958 | | P1NP (ng/ml) | 22.97 (14.54–40.21) | 30.53 (20.75–41.07) | 0.3276 | | Decreased P1NP N (%) | 2 (4.35%) | 2 (6.06%) | 0.7320 | | Age at diagnosis (year) | 34.81 ± 8.19 | 33.66 ± 8.62 | 0.4022 | | Cushing duration (years) | 3.11 ± 2.98 | 3.74 ± 4.47 | 0.3251 | | BMI (kg/m2) | 26.40 ± 5.20 | 25.24 ± 3.41 | 0.1228 | | SBP (mm Hg) | 137.13 ± 16.94 | 142.79 ± 17.64 | 0.0533 | | DBP (mm Hg) | 89.76 ± 13.43 | 97.07 ± 13.69 | 0.0016 | | HBP % | 41 (51.67%) | 51 (76.12%) | 0.0075 | | ALT (mmol/L) | 26.50 (18.00–42.00) | 33.00 (22.00–56.00) | 0.0906 | | Serum creatinine (mmol/L) | 55.90 ± 13.35 | 66.15 ± 24.33 | 0.0026 | | UA (mmol/L) | 0.32 ± 0.10 | 0.36 ± 0.10 | 0.0202 | | HbA1c % | 5.90 (5.50–6.55) | 5.75 (5.30–6.50) | 0.5194 | | DM N (%) | 27 (45.76%) | 32 (62.75%) | 0.0749 | | CHOL (mmol/L) | 5.06 ± 1.47 | 5.57 ± 1.30 | 0.037 | | TG (mmol/L) | 1.32 (0.91–2.13) | 1.67 (1.09–2.46) | 0.1718 | | HDL (mmol/L) | 1.45 ± 0.42 | 1.50 ± 0.39 | 0.4801 | | LDL (mmol/L) | 3.23 ± 0.87 | 3.48 ± 0.94 | 0.1125 | | Dyslipidemia N (%) | 31 (44.29%) | 30 (47.62%) | 0.7001 | | IGF-1 index | 0.79 (0.60–1.02) | 0.59 (0.43–0.76) | 0.0001 | | IGF-1 index >1 N (%) | 18 (26.87%) | 3 (4.84%) | 0.0007 | | TSH (mIU/L) | 1.08 (0.69–1.59) | 0.83 (0.59–1.42) | 0.1304 | | FT3 (nmol/L) | 3.98 (3.47–4.45) | 3.54 (3.16–4.04) | 0.0169 | | FT4 (nmol/L) | 13.70 (12.70–15.26) | 13.48 (11.59–16.00) | 0.6259 | | Testosterone (ng/L) | | Male | 4.47 (3.55–6.47) | 6.06 (4.04–9.38) | 0.1596 | | Female | 1.54 (0.97–2.05) | 2.10 (1.33–2.89) | 0.0012 | | Estradiol (ng/L) | | Male | 62.6 (47.5–88.1) | 80.25 (38.2–109.3) | 0.8229 | | Female | 172.95 (116.25–301.70) | 137.50 (89.70–251.50) | 0.1754 | | Normal menstruation in female N (%) | 35 (50.7%) | 16 (32.6%) | 0.059 | | 24h UFC (nmol/24 h) | 287.28 (172.32–643.40) | 345.69 (187.92–722.88) | 0.2771 | | F8 am (ug/dL) | 26.18 (17.81–31.96) | 28.08 (22.22–33.08) | 0.0550 | | F24 pm (ug/dL) | 17.80 (13.75–22.77) | 22.31 (17.95–29.62) | 0.0006 |
|
|
